Geneoscopy signs multi-year agreement with Labcorp to distribute noninvasive multi-target stool RNA (mt-sRNA) colorectal cancer screening test

Nov. 17, 2023
Collaboration expected to increase provider and patient access to potentially life-saving colorectal cancer screening that enables earlier disease detection.

Geneoscopy Inc. announced a strategic collaboration with Labcorp. This multi-year agreement will increase access to Geneoscopy’s next-generation colorectal cancer screening test, which offers at-home collection and high sensitivity for early cancer detection.

Geneoscopy’s test is under FDA review. Once approved by the FDA, Labcorp will offer the test, which will be performed by Geneoscopy, enabling healthcare customers to conveniently order it through Labcorp as part of their comprehensive screening programs.

Geneoscopy’s multi-target stool RNA (mt-sRNA) biomarker panel is designed to detect precancerous lesions and colorectal cancer. The company has submitted a Premarket Approval Application (PMA) to the FDA based on the favorable results from the pivotal CRC-PREVENT trial, in which Geneoscopy’s test demonstrated high sensitivity for CRC and advanced adenomas. Notably, for younger participants (ages 45 to 49), sensitivity for CRC was 100%.

Geneoscopy release